Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 18157117.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We enhanced the activities of two agonist antibodies specific for the thrombopoietin receptor (c-MPL) by switching domains within their constant regions to those of different antibody isotypes. Our results suggest the importance of the hinge region in modulating agonist activity. The antibodies' thrombopoietin-like activity in vitro and in vivo, as well as the desirable pharmacokinetic profile conferred by retaining the whole-IgG structure, suggests that they provide a valuable option for treating thrombocytopenia.
Medical subject headings
- Antibodies, Monoclonal
- Genetic Enhancement
- Protein Engineering
- Receptors, Thrombopoietin